ClinicalTrials.gg
RecruitingNCT06064825TREOCAPA-LTUpdated Apr 16, 2026

Long Term Follow-up of the TREOCAPA Study (TREOCAPA-LT)

An observational study in Patency of the Ductus Arteriosus Acetaminophen Extreme Prematurity, sponsored by Institut National de la Santé Et de la Recherche Médicale, France. Recruiting at 8 sites in France. Open to participants aged 23 Months to 27 Months. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by Institut National de la Santé Et de la Recherche Médicale, France · Observational

How we know

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
500
Ages
23 Months to 27 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 205 studies in Premature Birth with a site in France — 40 open to participants now, 46 under way, 2 of them phase 3. Premature Birth · France.

Planned enrollment
23rd of 99
500 · median 130
Started
2023
with 10 others
Observational
99 of 205
21 open now
Primary completion
2026-12
later than 21 of 45 live
Registered
174th of 205
by date

Among the 205 studies in Premature Birth with a site in France, this one is the 23rd largest by planned enrollment of the 99 observational ones that give a count, is one of 11 that started in 2023, is one of 99 observational ones, reaches primary completion later than 21 of the 45 other live ones, and was the 174th registered.

Premature Birth

2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.

Browse Premature Birth studies →

Open to participants now

40 of the 205 studies in Premature Birth with a site in France are open now. Recruiting first, the newest first:

34 more — sign in →

All 40 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.

This study: 23 Months to 27 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 205 studies in Premature Birth with a site in France, or all of them as a file.
02

Study summary

The ductus arteriosus (DA) is a large channel connecting the main pulmonary trunk with the descending aorta. In extremely preterm infants, the DA frequently fails to close and this results in a condition called patent ductus arteriosus (PDA). In these patients, PDA has been associated with increased mortality and morbidity in the neonatal period, and neonatal morbidities may in turn be associated with later deficits in cognitive functioning. PDA treatment with COX inhibitors, as ibuprofen or indomethacin, aiming at closing the PDA have been associated with numerous adverse effects and failed to demonstrate significant clinical benefits. Early treatment of PDA with paracetamol (acetaminophen ) has been proposed as an alternative to COX inhibitors. The ongoing pan-European TREOCAPA phase III study (NCT04459117) is a multicentre, double-blind, randomised, placebo-controlled superiority trial that assesses prophylactic use of paracetamol to improve survival without severe neonatal morbidity until discharge from hospital in infants of 23-28 weeks of gestational age. As long-term follow-up was not planned by the TREOCAPA protocol, TREOCAPA-LT study will use an existing European research infrastructure, the RECAP Preterm platform (https://recap-preterm.eu/), to follow-up the patients enrolled in the TREOCAPA trial using a parent-report questionnaire at 2 years of corrected age.

The TREOCAPA-LT primary hypothesis is that there will be improved cognitive outcome at 2 years of corrected age in children born at less than 29 weeks of gestational age who were treated with paracetamol during the first 5 days of life in the TREOCAPA phase III trial.

Read the detailed description

The ductus arteriosus (DA) is a large channel found normally in all mammalian foetuses, connecting the main pulmonary trunk with the left-sided descending aorta. During fetal life, it diverts most of the combined ventricular output away from the lungs toward the placenta. In full-term newborns, the DA is functionally open in all newborns and its constriction and closure, within 24 to 48 hours after delivery, are part of the normal process of postnatal adaptation. In extremely preterm infants, ie, those born before 29 weeks of gestation, the DA frequently fails to close and this results in a condition called patent ductus arteriosus (PDA). In these patients, PDA has been associated with increased mortality and morbidity in the neonatal period, and neonatal morbidities may in turn be associated with later deficits in cognitive functioning. Inhibition of prostaglandin synthesis, through inhibition of the cyclo-oxygenase (COX) enzymes, results in ductal constriction. However, treatments with COX inhibitors, as ibuprofen or indomethacin, aiming at closing the PDA have been associated with numerous adverse effects and failed to demonstrate significant clinical benefits. Prophylactic use of indomethacin or ibuprofen has been shown to reduce subsequent development of PDA but not to reduce mortality or morbidity. Further, investigations of early cardiac ultrasound-targeted treatment of a large PDA using indomethacin and ibuprofen do not show efficacy on primary outcomes of neonatal death or morbidity. Although this evidence base shows that prophylactic treatment by indomethacin or ibuprofen cannot be recommended, evidence from observational studies suggests that early (during the first 3 days of life) conservative treatment should not be recommended either. Two observational studies indicated that ignoring a PDA during the first days of life is associated with increase in mortality or morbidity. Our interpretation of these results is that screening echocardiography of large ductus arteriosus and early targeted treatment using echocardiography reduce pulmonary haemorrhage, but that the use of drugs with severe adverse effects may cancel expected beneficial effects on the occurrence of death or morbidity.

The use of a medication with an effect on PDA and that has fewer adverse effects is therefore desirable. Early treatment of PDA with paracetamol (acetaminophen) has been proposed as an alternative to COX inhibitors. According to a recent meta-analysis, use of paracetamol has a comparable effectiveness to close a PDA, and fewer harmful effects. However, only few extremely preterm infants were included in this meta-analysis. Therefore, efficacy and safety of paracetamol for PDA treatment in this population required further studies.

The ongoing pan-European TREOCAPA phase III study (NCT04459117) is a multicentre, double-blind, randomised, placebo-controlled superiority trial that assesses prophylactic use of paracetamol to improve survival without severe neonatal morbidity until discharge from hospital in infants of 23-28 weeks of gestational age.12 The trial has been powered to identify an absolute difference of 10% in the primary outcome, survival without severe neonatal morbidity (defined as any of: bronchopulmonary dysplasia grade 3 according to National Institute of Health criteria, necrotising enterocolitis stage 2 or 3 using Bell's criteria, intraventricular haemorrhage grade III or IV using the classification of Papile et al, or any evidence of cystic periventricular leukomalacia), corresponding to an increase from 50% to 60% in the rate between groups at hospital discharge. It aims to recruit 398 infants born at 27-28 weeks of gestation, and 396 infants born at 23-26 weeks of gestation. The first patients were recruited in October 2020 and the recruitment period is anticipated to last until April 2024 at the latest.

The TREOCAPA phase III trial is ambitious and innovative in its scope, including more than 40 hospitals in 16 countries. However, long-term follow-up was not included in the TREOCAPA protocol. The follow-up of infants enrolled in clinical trials enables to measure the long-term effectiveness and safety of interventions performed in the neonatal period. In particular for exposition to paracetamol in the neonatal period, data from randomized studies are very limited, while long-term adverse effects of paracetamol, including notably behavioral problems, have been raised. There is hence a need to understand longer term outcomes for the infants enrolled in this study, as these longer-term endpoints correspond to important patient-valued outcomes and are critical to determining the comparative effectiveness of interventions. The working hypothesis, if the intervention has a positive impact on short-term endpoints, is that longer term outcomes will be better in the intervention group, reflecting reduced morbidity at discharge home from the neonatal hospitalisation.

As long-term follow-up was not planned by the TREOCAPA phase III protocol, TREOCAPA-LT study will use an existing European research infrastructure, the RECAP Preterm platform to follow-up patients enrolled in the TREOCAPA cohort at 2 years of corrected age. This platform federates 23 European longitudinal observational cohorts of children born very preterm. The platform includes expertise, tools and infrastructure to follow patients enrolled in trials. By integrating trial follow-up in this platform, it is also possible to compare patients enrolled in the TREOCAPA trial with those from population-based samples, allowing assessment of transportability of trial results.

Follow-up at 2 years of age is recommended as the focus for the first phase of long-term outcome monitoring and has become the de facto age which is used in many published and ongoing clinical trials. Furthermore, many hospital services provide follow-up for their patients until at least 2 years of age, and research contact with the families at this point provides an opportunity to maintain contact and demonstrate to patients the ongoing importance of their involvement in the study.

The TREOCAPA-LT primary hypothesis is that there will be improved cognitive outcome at 2 years of corrected age in children born at less than 29 weeks of gestational age who were treated with paracetamol during the first 5 days of life in the TREOCAPA trial.

Secondary hypotheses are that, among children treated with paracetamol/acetaminophen during the first 5 days of life:

  1. There will be reduced moderate or severe neurodevelopmental impairment, defined as the presence of at least one of the following: PARCA-R non-verbal cognitive score less than two standard deviations below the mean (score \<70) moderate-severe motor impairment, unilateral or bilateral deafness or blindness.
  2. There will be reduced need for secondary hospitalisations following the initial neonatal hospitalisation.
  3. There will be reduced long term health care utilisation costs associated with extremely preterm birth.

Secondary hypotheses also relate to the use of the RECAP Preterm platform of observational VPT cohorts in this study. These are that:

  1. As a trial population, the children born VPT included in the TREOCAPA-LT study will differ from those included in population-based observational cohorts in their perinatal characteristics and possibly in their health and developmental outcomes.
  2. That these differences in population characteristics can affect the transportability of the trial results to other populations of VPT infants.
03

Conditions studied

  • Patency of the Ductus Arteriosus Acetaminophen Extreme Prematurity

Keywords

  • Premature infants
  • persistent ductus arteriosus
  • paracetamol/acetaminophen
  • long term outcome
04

Who can participate

Ages eligible
23 Months to 27 Months
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population for the follow-up study of the TREOCAPA trial consists of all children included in phase III of the trial from centres participating in the follow-up study. The parents of children who survived to two years corrected age and meet the criteria for inclusion will be offered the opportunity to complete the questionnaire.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • were included in the TREOCAPA phase III RCT in participating centres
  • are aged between 23.5 and 27.5 months corrected age during the study period

Exclusion criteria

Exclusion Criteria:

  • if the local investigator does not have up-to-date contact information allowing contact with parents
  • if the child's vital status cannot be ascertained
  • if the child is nearing the end of his life or experiencing a severe medical event as assessed by the local investigator
  • if the child has become subject to a legal protection measure preventing their ongoing participation in clinical research
  • if either parent or guardian opts out of participating
  • language barrier
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • patients received the investigational medicinal product acetaminophen in their first 5 days of life

    This group of patients received the investigational product in their first 5 days of life during the Treocapa trial

    Other: 2 year follow-up of neurodevelopment using a parental questionnaire

  • patients received the placebo (NaCl) in their first 5 days of life

    This group of patients received the placebo in their first 5 days of life during the Treocapa trial

    Other: 2 year follow-up of neurodevelopment using a parental questionnaire

Interventions

  • Other2 year follow-up of neurodevelopment using a parental questionnaire

    A parental questionnaire, using the PARCA-R instrument, is given to measure cognitive outcome at 2 years of corrected age for children included in the Treocapa Trial

06

What researchers measure

Primary outcomes

  1. Non-verbal cognition at 2 years corrected age

    Non-verbal cognitive (NVC) scale score from the Parent Report of Children's Abilities-Revised (PARCA-R) questionnaire, administered using an on-line parental questionnaire. The score is standardised such that it has a mean of 100 and a standard deviation of 15. Lower scores mean worse outcomes.

    Time frame: from 23,5 to 27,5 months of corrected age

Secondary outcomes

  1. Survival without moderate or severe cognitive impairment

    Definied as survival to 2 years corrected age with a PARCA-R NVC scale score less than 2 standard deviations below the mean.

    Time frame: from 23,5 to 27,5 months of corrected age

  2. Survival without moderate or severe neurodevelopmental impairment based on the presence of at least one of the impairments in the description :

    1. the PARCA-R NVC \< 2 standard deviations below the mean; 2. moderate to severe motor impairment, as measured using parent reported questions, defined as a child unable to: walk without assistance or aids or sit or hold their head up without support19; 3. unilateral or bilateral deafness or blindness as measured by parent reported questions: if the child is deaf or has functional hearing loss requiring correction with aids but still has difficulty hearing, or if the child is blind or able to see light only19.

    Time frame: from 23,5 to 27,5 months of corrected age

  3. Health service use and costs

    Reported by parents in the questionnaire, using questions on visits to health service providers and other costs associated with care of the children that have been used in previous European studies

    Time frame: from 23,5 to 27,5 months of corrected age

Other outcomes

  1. Comparisons of the results with observational cohorts of very preterm infants for maternal sociodemographic characteristics

    Descriptive statistics on maternal sociodemographic characteristics

    Time frame: This analysis will be carried during the 12 months after the end of data collection.

  2. Comparisons of the results with observational cohorts of very preterm infants for gestational age

    Descriptive statistics on gestational age

    Time frame: This analysis will be carried during the 12 months after the end of data collection.

  3. Comparisons of the results with observational cohorts of very preterm infants on sex

    Descriptive statistics on sex

    Time frame: This analysis will be carried during the 12 months after the end of data collection.

  4. Comparisons of the results with observational cohorts of very preterm infants for complication of pregnancy

    Descriptive statistics on complications of pregnancy

    Time frame: This analysis will be carried during the 12 months after the end of data collection.

  5. Comparisons of the results with observational cohorts of very preterm infants for birth

    Descriptive statistics on complication of birth

    Time frame: This analysis will be carried during the 12 months after the end of data collection.

  6. Comparisons of the results with observational cohorts of very preterm infants for neonatal morbidities

    Descriptive statistics on neonatal morbidities

    Time frame: This analysis will be carried during the 12 months after the end of data collection.

  7. Comparisons of the results with observational cohorts of very preterm infants for mortality

    Descriptive statistics on mortality

    Time frame: This analysis will be carried during the 12 months after the end of data collection.

  8. Comparisons of the results with observational cohorts of very preterm infants for neurodevelopment

    Descriptive statistics on two-year neurodevelopment

    Time frame: This analysis will be carried during the 12 months after the end of data collection.

07

Study locations

8 of 8 sites recruiting
08

References and documents

Publications

  • Clyman RI. Ibuprofen and patent ductus arteriosus. N Engl J Med. 2000 Sep 7;343(10):728-30. doi: 10.1056/NEJM200009073431009. No abstract available. PubMed 10974138 ↗
  • Hamrick SEG, Sallmon H, Rose AT, Porras D, Shelton EL, Reese J, Hansmann G. Patent Ductus Arteriosus of the Preterm Infant. Pediatrics. 2020 Nov;146(5):e20201209. doi: 10.1542/peds.2020-1209. PubMed 33093140 ↗
  • Mitra S, de Boode WP, Weisz DE, Shah PS. Interventions for patent ductus arteriosus (PDA) in preterm infants: an overview of Cochrane Systematic Reviews. Cochrane Database Syst Rev. 2023 Apr 11;4(4):CD013588. doi: 10.1002/14651858.CD013588.pub2. PubMed 37039501 ↗
  • Fowlie PW, Davis PG, McGuire W. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev. 2010 Jul 7;2010(7):CD000174. doi: 10.1002/14651858.CD000174.pub2. PubMed 20614421 ↗
  • Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database Syst Rev. 2018 Sep 28;9(9):CD003481. doi: 10.1002/14651858.CD003481.pub7. PubMed 30264852 ↗
  • Kluckow M, Jeffery M, Gill A, Evans N. A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed. 2014 Mar;99(2):F99-F104. doi: 10.1136/archdischild-2013-304695. Epub 2013 Dec 6. PubMed 24317704 ↗
  • Roze JC, Cambonie G, Le Thuaut A, Debillon T, Ligi I, Gascoin G, Patkai J, Beuchee A, Favrais G, Flamant C, Durrmeyer X, Clyman R. Effect of Early Targeted Treatment of Ductus Arteriosus with Ibuprofen on Survival Without Cerebral Palsy at 2 Years in Infants with Extreme Prematurity: A Randomized Clinical Trial. J Pediatr. 2021 Jun;233:33-42.e2. doi: 10.1016/j.jpeds.2020.12.008. Epub 2020 Dec 9. PubMed 33307111 ↗
  • Liebowitz M, Clyman RI. Prophylactic Indomethacin Compared with Delayed Conservative Management of the Patent Ductus Arteriosus in Extremely Preterm Infants: Effects on Neonatal Outcomes. J Pediatr. 2017 Aug;187:119-126.e1. doi: 10.1016/j.jpeds.2017.03.021. Epub 2017 Apr 7. PubMed 28396025 ↗
  • Roze JC, Cambonie G, Marchand-Martin L, Gournay V, Durrmeyer X, Durox M, Storme L, Porcher R, Ancel PY; Hemodynamic EPIPAGE 2 Study Group. Association Between Early Screening for Patent Ductus Arteriosus and In-Hospital Mortality Among Extremely Preterm Infants. JAMA. 2015 Jun 23-30;313(24):2441-8. doi: 10.1001/jama.2015.6734. PubMed 26103028 ↗
  • Clyman RI, Liebowitz M, Kaempf J, Erdeve O, Bulbul A, Hakansson S, Lindqvist J, Farooqi A, Katheria A, Sauberan J, Singh J, Nelson K, Wickremasinghe A, Dong L, Hassinger DC, Aucott SW, Hayashi M, Heuchan AM, Carey WA, Derrick M, Fernandez E, Sankar M, Leone T, Perez J, Serize A; PDA-TOLERATE (PDA: TO LEave it alone or Respond And Treat Early) Trial Investigators. PDA-TOLERATE Trial: An Exploratory Randomized Controlled Trial of Treatment of Moderate-to-Large Patent Ductus Arteriosus at 1 Week of Age. J Pediatr. 2019 Feb;205:41-48.e6. doi: 10.1016/j.jpeds.2018.09.012. Epub 2018 Oct 16. PubMed 30340932 ↗
  • Jasani B, Mitra S, Shah PS. Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants. Cochrane Database Syst Rev. 2022 Dec 15;12(12):CD010061. doi: 10.1002/14651858.CD010061.pub5. PubMed 36519620 ↗
  • Marlow N, Doyle LW, Anderson P, Johnson S, Bhatt-Mehta V, Natalucci G, Darlow BA, Davis JM, Turner MA; International Neonatal Consortium (INC). Assessment of long-term neurodevelopmental outcome following trials of medicinal products in newborn infants. Pediatr Res. 2019 Nov;86(5):567-572. doi: 10.1038/s41390-019-0526-1. Epub 2019 Aug 9. PubMed 31398720 ↗
  • Masarwa R, Levine H, Gorelik E, Reif S, Perlman A, Matok I. Prenatal Exposure to Acetaminophen and Risk for Attention Deficit Hyperactivity Disorder and Autistic Spectrum Disorder: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Cohort Studies. Am J Epidemiol. 2018 Aug 1;187(8):1817-1827. doi: 10.1093/aje/kwy086. PubMed 29688261 ↗
  • Baker BH, Lugo-Candelas C, Wu H, Laue HE, Boivin A, Gillet V, Aw N, Rahman T, Lepage JF, Whittingstall K, Bellenger JP, Posner J, Takser L, Baccarelli AA. Association of Prenatal Acetaminophen Exposure Measured in Meconium With Risk of Attention-Deficit/Hyperactivity Disorder Mediated by Frontoparietal Network Brain Connectivity. JAMA Pediatr. 2020 Nov 1;174(11):1073-1081. doi: 10.1001/jamapediatrics.2020.3080. PubMed 32986124 ↗
  • Inoue K, Ritz B, Ernst A, Tseng WL, Yuan Y, Meng Q, Ramlau-Hansen CH, Strandberg-Larsen K, Arah OA, Obel C, Li J, Olsen J, Liew Z. Behavioral Problems at Age 11 Years After Prenatal and Postnatal Exposure to Acetaminophen: Parent-Reported and Self-Reported Outcomes. Am J Epidemiol. 2021 Jun 1;190(6):1009-1020. doi: 10.1093/aje/kwaa257. PubMed 33230558 ↗
  • Johnson S, Bountziouka V, Brocklehurst P, Linsell L, Marlow N, Wolke D, Manktelow BN. Standardisation of the Parent Report of Children's Abilities-Revised (PARCA-R): a norm-referenced assessment of cognitive and language development at age 2 years. Lancet Child Adolesc Health. 2019 Oct;3(10):705-712. doi: 10.1016/S2352-4642(19)30189-0. Epub 2019 Aug 8. PubMed 31402196 ↗
  • Draper ES, Zeitlin J, Manktelow BN, Piedvache A, Cuttini M, Edstedt Bonamy AK, Maier R, Koopman-Esseboom C, Gadzinowski J, Boerch K, van Reempts P, Varendi H, Johnson SJ; EPICE group. EPICE cohort: two-year neurodevelopmental outcomes after very preterm birth. Arch Dis Child Fetal Neonatal Ed. 2020 Jul;105(4):350-356. doi: 10.1136/archdischild-2019-317418. Epub 2019 Nov 5. PubMed 31690558 ↗
  • Seppanen AV, Bodeau-Livinec F, Boyle EM, Edstedt-Bonamy AK, Cuttini M, Toome L, Maier RF, Cloet E, Koopman-Esseboom C, Pedersen P, Gadzinowski J, Barros H, Zeitlin J; Effective Perinatal Intensive Care in Europe (EPICE) research group. Specialist health care services use in a European cohort of infants born very preterm. Dev Med Child Neurol. 2019 Jul;61(7):832-839. doi: 10.1111/dmcn.14112. Epub 2018 Dec 3. PubMed 30508225 ↗
  • Seppanen AV, Draper ES, Petrou S, Barros H, Aubert AM, Andronis L, Kim SW, Maier RF, Pedersen P, Gadzinowski J, Lebeer J, Aden U, Toome L, van Heijst A, Cuttini M, Zeitlin J; SHIPS Research Group. High Healthcare Use at Age 5 Years in a European Cohort of Children Born Very Preterm. J Pediatr. 2022 Apr;243:69-77.e9. doi: 10.1016/j.jpeds.2021.12.006. Epub 2021 Dec 16. PubMed 34921871 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2023 (actual). Primary completion is estimated for Dec 2026, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2023
First posted
Oct 3, 2023
StartActual
Dec 12, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2027
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06064825
Responsible party
Sponsor
First posted
Oct 3, 2023
Start date
Dec 12, 2023
Primary completion
Dec 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Apr 16, 2026

Study contacts

Gilles Cambonie, MD/PHD
Contact
g-cambonie@chu-montpellier.fr
+33467336609
Andrei Morgan, FRCPCH, MSc, PhD
Contact
andrei.morgan@inserm.fr
+33171722987
Jennifer Zeitlin
study director · Institut National de la Santé Et de la Recherche Médicale, France

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion